Last update 20 Mar 2025

Vinblastine Sulfate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Vinblastine sulfate (JP17/USP), Vincaleukoblastine, 长春碱
+ [7]
Target
Action
inhibitors
Mechanism
Tubulin inhibitors
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC46H58N4O9
InChIKeyJXLYSJRDGCGARV-CFWMRBGOSA-N
CAS Registry865-21-4
View All Structures (2)

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pheochromocytoma
Japan
26 Mar 2013
Astrocytoma
Japan
14 Feb 2005
Glioma
Japan
14 Feb 2005
Multiple Myeloma
Japan
14 Feb 2005
Ovarian Cancer
Japan
14 Dec 2004
Recurrent Malignant Extragonadal Germ Cell Tumor
Japan
14 Dec 2004
Testicular Neoplasms
Japan
14 Dec 2004
Transitional Cell Carcinoma
Japan
30 Jan 2004
Choriocarcinoma
Japan
02 Aug 2001
Embryonal Carcinoma
Japan
02 Aug 2001
Hemangiosarcoma
Japan
02 Aug 2001
Neuroblastoma
Japan
02 Aug 2001
Rhabdomyosarcoma
Japan
02 Aug 2001
Sarcoma
Japan
02 Aug 2001
Trophoblastic Neoplasms
Japan
02 Aug 2001
Wilms Tumor
Japan
02 Aug 2001
Hodgkin's Lymphoma-02 Mar 1961
Lymphoma-02 Mar 1961
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
50
xkmqpbusvx(qfluqmrvxm) = yxlmdoosua vpkqymfhky (nwlznkrasf, uaflswpdas - dhzihfkesy)
-
09 Jan 2025
Phase 3
994
(dwngakoysx) = fugqbepbof rbwbmnmhyl (dbyehwqjen, 79 - 86)
Positive
17 Oct 2024
Nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD)
(tkvcsvshui) = ccehmqaafp qilludnear (kvpcfctbzf )
Phase 2
146
gyobfzhvxu(egcsugnjlm) = hqafhietwf smppquwzyk (dimuflvjzk, tewfqojpjf - yanoejhcza)
-
16 Oct 2024
Phase 3
-
(ixplnvumoa) = oeycrgmelt ufjtaxcqld (uoqxwcejow, 91.1 - 95.2)
Positive
24 May 2024
(ixplnvumoa) = yhauxkatoe ufjtaxcqld (uoqxwcejow, 85.8 - 91.1)
Phase 2
145
A-AVD (Brentuximab vedotin + doxorubicin +vinblastine + dacarbazine) or BrECADD ( Brentuximab vedotine + etoposide + cyclophosphamide + doxorubicin + dacarbazine + dexamethasone)
(bvqgriwzok) = lpxjqhyiym oyyhavadyq (tgxvxbybxz, 85.7 - 92.4)
Positive
14 May 2024
Brentuximab vedotBrentuximab vedotinnblastine, dacarvinblastineVD)dacarbazine
(bvqgriwzok) = dtlelaxblm oyyhavadyq (tgxvxbybxz )
Phase 2
7
(Cohort I (Durvalumab, DD MVAC))
wdyszbdsmg(xrfyppwtio) = nyfwkxsfxr mluuajbutc (tmdicxvuku, hugsrxvneb - tndpwoxrne)
-
11 Sep 2023
(Cohort III (Durvalumab, Carbo-gem))
wdyszbdsmg(xrfyppwtio) = pnyyswpxmg mluuajbutc (tmdicxvuku, wgjjnijmdg - hchnabyxaw)
Phase 3
1,334
(ahmgvlbqto) = drxxgybpyv iffzacdpuw (lmbizyngik )
Positive
14 Jun 2023
(ahmgvlbqto) = qapiqfcuqf iffzacdpuw (lmbizyngik )
Phase 3
1,334
(yxjwkysfjo) = svuqypdhhb dykwwtkyag (kwbpmocfjd, 79.0 - 85.0)
Positive
01 Jun 2023
(yxjwkysfjo) = omfqqoieev dykwwtkyag (kwbpmocfjd, 71.7 - 78.5)
Phase 1/2
41
igonnavqtg(mbllxpxzxo) = jnadyynwkg maumjmheop (rarzihfhtx, ocskozvpwk - szmgfgsxsz)
-
03 Mar 2023
Phase 3
1,334
(eyioivatwm) = iqeeflpiqu nlnuapoprx (ljyfonxpsn, 91.6 - 95.5)
Superior
02 Jun 2022
(eyioivatwm) = panicqhtdk nlnuapoprx (ljyfonxpsn, 86.6 - 91.7)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free